Oxytocin's Effect on the Advantageous- and Disadvantageous-inequity

Healthy Clinical Trial

Official title:

Oxytocin Modulates the Processing of the Advantageous- and Disadvantageous-inequity

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT06405737
• Other study ID #: UESTC-neuSCAN-88
• Status: Active, not recruiting
• Phase: N/A
• Start date: January 7, 2024
• Est. completion date: June 20, 2024

Study information

• Verified date: May 2024
• Source: University of Electronic Science and Technology of China
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and whether oxytocin has similar effects on them or not.

Description:

The main aim of the study is to investigate whether intranasal oxytocin modulates advantageous- and disadvantageous-inequity and its underlying neural mechanisms and whether oxytocin has similar effects on them or not. A double-blinded, placebo-controled, between-subject design is employed in this study. In a randomized order, a total of 80 healthy males are instructed to self-administrated intranasal spray of oxytocin or placebo. A modified inequity decision-making task starts 45 minutes after treatment with behavioral (fairness rating, preference rating and the choice rate of unequal option) and fMRI data being collected during this task. Personality traits of subjects are assessed using validated Chinese version questionnaires including the Beck Depression Inventory (BDI-II), State-Trait Anxiety Inventory (STAI), Autism Spectrum Quotient (ASQ), Sensitivity to Punishment and Sensitivity to Reward Questionnaire (SPSRQ), Behavioral Inhibition System and Behavioral Activation System Scale (BIS/BAS). Subjects are asked to complete Positive and Negative Affect Schedule (PANAS) when they just arrive, before and after the task.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: June 20, 2024
• Est. primary completion date: May 20, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Healthy subjects without past or current psychiatric or neurological disorders

Exclusion Criteria:

• history of head injury

• pregnant,menstruating,taking oral contraceptives

• medical or psychiatric illness.

• excessive head movement (> 3mm) during scanning

Related Conditions & MeSH terms

• Healthy

Intervention

Drug:
• Intranasal oxytocin
Subject assigned to receive intranasal administration of oxytocin (24 IU).
• Intranasal placebo
Subjects assigned to receive intranasal administration of placebo (24 IU).

Locations

Country	Name	City	State
China	University of Electronic Science and Technology of China (UESTC)	Chengdu	Sichuan

Sponsors (1)

Lead Sponsor	Collaborator
University of Electronic Science and Technology of China

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Behavioral index: fairness rating scores	Participants are instructed to rate their perceived levels of fairness to the allocation using a 9-point Likert scale within 4 seconds (1 = very unfair, 9 = very fair).	45-75 minutes after treatment administration
Primary	Behavioral index: preference rating scores	Participants are instructed to rate their perceived levels of preference to the allocation using a 9-point Likert scale within 4 seconds (1 = not at all, 9 = very preferable).	45-75 minutes after treatment administration
Primary	Neural indices: fMRI-based measures of the outcome presentation stage	Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are confronted with monetary allocations (advantageous-inequity, disadvantageous-inequity, and fair).	45-75 minutes after treatment administration
Secondary	Behavioral index: choice rate of unequal option	Participants are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.	45-75 minutes after treatment administration
Secondary	Neural indices: fMRI-based measures of outcome and re-decision stages	Functional magnetic resonance imaging (fMRI) is employed to assess participants' blood-oxygen-level dependent signals when they are instructed to make a hypothetical choice between the actual allocation in the current trial and the other fair option if they were given another chance to re-choose.	45-75 minutes after treatment administration